DelveInsight’s, “Interleukin-12 Expression Stimulants – Pipeline Insight, 2022,” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Interleukin-12 Expression Stimulants pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Interleukin-12 Expression Stimulants: Overview
Interleukin-12 (IL-12) is a potent, pro-inflammatory type 1 cytokine that has long been studied as a potential immunotherapy for cancer. Interleukin 12, or IL-12, is a cytokine (a type of signaling protein) that activates the immune system after being released from cells. The development of strategies which maximize IL-12 delivery to the tumor microenvironment while minimizing systemic exposure are of increasing interest. Diverse IL-12 delivery systems, from immunocytokine fusions to polymeric nanoparticles, have demonstrated robust antitumor immunity with reduced adverse events in preclinical studies. Perspectives on how IL-12-based immunotherapies may be utilized for widespread clinical application in the very near future are offered.
"Interleukin-12 Expression Stimulants - Pipeline Insight, 2022" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Interleukin-12 Expression Stimulants pipeline landscape is provided which includes the disease overview and Interleukin-12 Expression Stimulants treatment guidelines. The assessment part of the report embraces, in depth Interleukin-12 Expression Stimulants commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Interleukin-12 Expression Stimulants collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
The companies and academics are working to assess challenges and seek opportunities that could influence Interleukin-12 Expression Stimulants R&D. The therapies under development are focused on novel approaches to treat/improve Interleukin-12 Expression Stimulants.
This segment of the Interleukin-12 Expression Stimulants report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Interleukin-12 Expression Stimulants Emerging Drugs
T3011: Immvira Pharma
ImmVira's MVR-T3011 oncolytic virus program has innovated with a genetically engineered oncolytic herpes simplex virus-1 (oHSV-1) to enhance the known oncolytic effects of oHSV-1. Through gene recombinant technologies, PD-1 antibody and interleukin-12 immune modulators are expressed within the virus. Oncolysis is achieved with additional immune response stimulation while keeping the boosted immune activity limited to the locality of MVR-T3011 to achieve a potentially favorable safety profile. The MVR-T3011 intratumoral program aims to target most solid malignant tumors with both remission rate improvement and safety improvement over immune modulator monotherapies. In January 2020, ImmVira and Shanghai Pharma Announce Clinical Collaboration and License Agreement for Commercialization of Novel Intratumoral Oncolytic Virus Immunotherapies. It is currently being evaluated in Phase II stage of development for the treatment of Breast cancer and Head and neck cancer.
INXN 2001: Ziopharm Oncology
INXN 2001 is injected intratumourally, and employs an adenoviral vector to directly deliver a gene, which expresses interleukin-12 (IL-12). An oral activator ligand (INXN 1001, veledimex) is then given to turn on expression of the gene locally. INXN-2001 is in phase II clinical trials with Veledimex by ZIOPHARM Oncology for the treatment of recurrent/metastatic breast cancer and phase I for glioblastoma or malignant glioma.
Further product details are provided in the report……..
This segment of the report provides insights about the different Interleukin-12 Expression Stimulants drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 8+ key companies which are developing the therapies for Interleukin-12 Expression Stimulants. The companies which have their Interleukin-12 Expression Stimulants drug candidates in the most advanced stage, i.e. phase II include Immvira Pharma.
DelveInsight’s report covers around 8+ products under different phases of clinical development like
Interleukin-12 Expression Stimulants pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Products have been categorized under various Molecule types such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Interleukin-12 Expression Stimulants therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Interleukin-12 Expression Stimulants drugs.
Current Treatment Scenario and Emerging Therapies:
Introduction
Executive Summary
Interleukin-12 Expression Stimulants: Overview
Pipeline Therapeutics
Therapeutic Assessment
Mid Stage Products (Phase II)
T3011: Immvira Pharma
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
TAK-605: Takeda
Drug profiles in the detailed report…..
Inactive Products
Interleukin-12 Expression Stimulants Key Companies
Interleukin-12 Expression Stimulants Key Products
Interleukin-12 Expression Stimulants- Unmet Needs
Interleukin-12 Expression Stimulants- Market Drivers and Barriers
Interleukin-12 Expression Stimulants- Future Perspectives and Conclusion
Interleukin-12 Expression Stimulants Analyst Views
Interleukin-12 Expression Stimulants Key Companies
Appendix
List of Table
Table 1: Total Products for Interleukin-12 Expression Stimulants
Table 2: Late Stage Products
Table 3: Mid Stage Products
Table 4: Early Stage Products
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Product Type
Table 7: Assessment by Stage and Product Type
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: Inactive Products
List of Figures
Figure 1: Total Products for Interleukin-12 Expression Stimulants
Figure 2: Late Stage Products
Figure 3: Mid Stage Products
Figure 4: Early Stage Products
Figure 5: Preclinical and Discovery Stage Products
Figure 6: Assessment by Product Type
Figure 7: Assessment by Stage and Product Type
Figure 8: Assessment by Route of Administration
Figure 9: Assessment by Stage and Route of Administration
Figure 10: Assessment by Molecule Type
Figure 11: Assessment by Stage and Molecule Type
Figure 12: Inactive Products
• ZIOPHARM Oncology
• Immvira Pharma
• Takeda
• Sanofi
• CaroGen
• OncoMyx Therapeutics
• Virogin Biotech
• Moderna Therapeutics
• Mallinckrodt plc
• Senti Biosciences
